author-photo

Yin-Hsun Feng

42

Papers

578

Citations

Citation Trend

Filter By

Papers (27) Sort By

Journal Conference Others

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Narrative review—cardiovascular evaluation before radiotherapy for patients with breast cancer and other malignancies

2021
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of the Pan-Asian Subgroup of patients in the NALA Trial: A Randomized Phase III NALA Trial Comparing Neratinib + Capecitabine (N+C) vs Lapatinib + Capecitabine (L+C) in Patients with HER2+ Metastatic Breast Cancer (mBC) Previously Treated with Two or more HER2-Directed Regimens

2021
Show All
- Source
- Cite
- Save
Citations (0)
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Stage III/IV: A Multicenter Study.

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (2)
The impact of COVID-19 on cardio-oncology care in Taiwan.

2021 Journal of the Formosan Medical Association
Show All
- Source
- Cite
- Save
Citations (0)
Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient

2021 Cureus
Show All
- Source
- Cite
- Save
Citations (0)
Additional file 1 of Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer

2020
Show All
- Source
- Cite
- Save
Citations (0)
Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.

2020 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (4)
46O Neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in Asians with HER2+ metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)